183 related articles for article (PubMed ID: 21984119)
1. Has the European union achieved a single pharmaceutical market?
Timur A; Picone G; DeSimone J
Int J Health Care Finance Econ; 2011 Dec; 11(4):223-44. PubMed ID: 21984119
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical price differences in the EU: investigation from cardiovascular disease drugs.
Timur A; Picone G
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):251-6. PubMed ID: 19527097
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical pricing, price controls, and their effects on pharmaceutical sales and research and development expenditures in the European Union.
Vogel RJ
Clin Ther; 2004 Aug; 26(8):1327-40; discussion 1326. PubMed ID: 15476914
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceutical Manufacturing in the EU and the EU-US Mutual Recognition Agreement.
Gaspar Ernesto LM; Dias Loureiro RM
PDA J Pharm Sci Technol; 2020; 74(6):617-626. PubMed ID: 32540862
[TBL] [Abstract][Full Text] [Related]
5. Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms.
Golec J; Vernon JA
Pharmacoeconomics; 2010; 28(8):615-28. PubMed ID: 20617857
[TBL] [Abstract][Full Text] [Related]
6. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
Orofino J; Soto J; Casado MA; Oyagüez I
Appl Health Econ Health Policy; 2010; 8(5):301-15. PubMed ID: 20804223
[TBL] [Abstract][Full Text] [Related]
7. Impact of European pharmaceutical price regulation on generic price competition: a review.
Puig-Junoy J
Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
[TBL] [Abstract][Full Text] [Related]
8. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure.
Magazzini L; Pammolli F; Riccaboni M
Eur J Health Econ; 2004 Jun; 5(2):175-82. PubMed ID: 15452754
[TBL] [Abstract][Full Text] [Related]
9. Does reimportation reduce price differences for prescription drugs? Lessons from the European Union.
Kyle MK; Allsbrook JS; Schulman KA
Health Serv Res; 2008 Aug; 43(4):1308-24. PubMed ID: 18355258
[TBL] [Abstract][Full Text] [Related]
10. Excessive pricing in the pharmaceutical industry: adding another string to the bow of EU competition law.
Danieli D
Health Econ Policy Law; 2021 Jan; 16(1):64-75. PubMed ID: 32434612
[TBL] [Abstract][Full Text] [Related]
11. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
Adamini S; Maarse H; Versluis E; Light DW
J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988
[TBL] [Abstract][Full Text] [Related]
12. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
[TBL] [Abstract][Full Text] [Related]
13. [Drugs in the European Union: the health-market complex].
Antoñanzas F; Rodríguez R; Sacristán JA; Illa R
Gac Sanit; 2005; 19(2):151-67. PubMed ID: 15860163
[TBL] [Abstract][Full Text] [Related]
14. Causes of drug shortages in the legal pharmaceutical framework.
De Weerdt E; Simoens S; Hombroeckx L; Casteels M; Huys I
Regul Toxicol Pharmacol; 2015 Mar; 71(2):251-8. PubMed ID: 25591547
[TBL] [Abstract][Full Text] [Related]
15. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
Martikainen J; Kivi I; Linnosmaa I
Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
[TBL] [Abstract][Full Text] [Related]
16. Medicinal products in the European Union--between harmonization and divergence.
Lojko N
Med Law; 2010 Mar; 29(1):61-76. PubMed ID: 22457998
[TBL] [Abstract][Full Text] [Related]
17. Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis.
Bocquet F; Paubel P; Fusier I; Cordonnier AL; Le Pen C; Sinègre M
Appl Health Econ Health Policy; 2014 Jun; 12(3):315-26. PubMed ID: 24578185
[TBL] [Abstract][Full Text] [Related]
18. [Competition and prices in the Mexican pharmaceutical market].
Molina-Salazar RE; González-Marín E; Carbajal-de Nova C
Salud Publica Mex; 2008; 50 Suppl 4():S496-503. PubMed ID: 19082261
[TBL] [Abstract][Full Text] [Related]
19. The economics of parallel trade.
Danzon PM
Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Medicine Prices in New Zealand and 16 European Countries.
Vogler S; Kilpatrick K; Babar ZU
Value Health; 2015 Jun; 18(4):484-92. PubMed ID: 26091603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]